MA39485A - Méthode de traitement de la dépression et du trouble dépressif majeur - Google Patents
Méthode de traitement de la dépression et du trouble dépressif majeurInfo
- Publication number
- MA39485A MA39485A MA039485A MA39485A MA39485A MA 39485 A MA39485 A MA 39485A MA 039485 A MA039485 A MA 039485A MA 39485 A MA39485 A MA 39485A MA 39485 A MA39485 A MA 39485A
- Authority
- MA
- Morocco
- Prior art keywords
- depressive disorder
- major depressive
- treating depression
- depression
- treating
- Prior art date
Links
- 208000024714 major depressive disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948529P | 2014-03-05 | 2014-03-05 | |
| US201462061417P | 2014-10-08 | 2014-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39485A true MA39485A (fr) | 2015-09-11 |
Family
ID=54055831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039485A MA39485A (fr) | 2014-03-05 | 2015-03-04 | Méthode de traitement de la dépression et du trouble dépressif majeur |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170137880A1 (fr) |
| EP (1) | EP3114239A4 (fr) |
| JP (1) | JP2017512204A (fr) |
| KR (1) | KR20160127126A (fr) |
| CN (1) | CN106536751A (fr) |
| AU (1) | AU2015227296A1 (fr) |
| CA (1) | CA2940683A1 (fr) |
| IL (1) | IL247379A0 (fr) |
| MA (1) | MA39485A (fr) |
| MX (1) | MX2016011384A (fr) |
| RU (1) | RU2016138574A (fr) |
| WO (1) | WO2015134585A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087735A1 (fr) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Procédé de traitement de la maladie de crohn |
| US20190216803A1 (en) | 2017-03-30 | 2019-07-18 | Rundle Research, LLC | Methods of treating depression with vortioxetine |
| HRP20211241T1 (hr) * | 2017-03-30 | 2021-11-12 | Rundle Research, LLC | Vortioksetin i inhibitori mao za liječenje depresije |
| EP3909600A1 (fr) * | 2020-05-12 | 2021-11-17 | International Centre For Genetic Engineering And Biotechnology - ICGEB | Protéine emid2 en tant que traitement anticancéreux |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2044043T5 (pl) * | 2006-06-16 | 2022-05-02 | H. Lundbeck A/S | Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych |
| CA2712075A1 (fr) * | 2008-01-17 | 2009-07-23 | Suregene Llc | Marqueurs genetiques de maladie mentale |
| WO2012031008A2 (fr) * | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Matières biologiques liées au cancer dans des microvésicules |
| US20130274133A1 (en) * | 2010-10-01 | 2013-10-17 | Rigshospitalet | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors |
| US9243464B2 (en) * | 2011-02-10 | 2016-01-26 | Baker Hughes Incorporated | Flow control device and methods for using same |
| WO2012109565A1 (fr) * | 2011-02-10 | 2012-08-16 | Neurotherics, Llc | Identification génétique de réponse à des médicaments antidépresseurs |
| RU2622082C2 (ru) * | 2011-11-14 | 2017-06-09 | Нестек С.А. | Анализы и способы выбора режима лечения пациента с депрессией |
-
2015
- 2015-03-04 JP JP2016554883A patent/JP2017512204A/ja active Pending
- 2015-03-04 US US15/123,072 patent/US20170137880A1/en not_active Abandoned
- 2015-03-04 EP EP15758563.9A patent/EP3114239A4/fr not_active Withdrawn
- 2015-03-04 RU RU2016138574A patent/RU2016138574A/ru not_active Application Discontinuation
- 2015-03-04 AU AU2015227296A patent/AU2015227296A1/en not_active Abandoned
- 2015-03-04 CA CA2940683A patent/CA2940683A1/fr not_active Abandoned
- 2015-03-04 MX MX2016011384A patent/MX2016011384A/es unknown
- 2015-03-04 MA MA039485A patent/MA39485A/fr unknown
- 2015-03-04 CN CN201580023401.1A patent/CN106536751A/zh active Pending
- 2015-03-04 WO PCT/US2015/018701 patent/WO2015134585A1/fr not_active Ceased
- 2015-03-04 KR KR1020167027125A patent/KR20160127126A/ko not_active Withdrawn
-
2016
- 2016-08-21 IL IL247379A patent/IL247379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106536751A (zh) | 2017-03-22 |
| KR20160127126A (ko) | 2016-11-02 |
| MX2016011384A (es) | 2017-05-01 |
| JP2017512204A (ja) | 2017-05-18 |
| CA2940683A1 (fr) | 2015-09-11 |
| IL247379A0 (en) | 2016-11-30 |
| AU2015227296A1 (en) | 2016-09-08 |
| EP3114239A1 (fr) | 2017-01-11 |
| US20170137880A1 (en) | 2017-05-18 |
| EP3114239A4 (fr) | 2017-10-11 |
| RU2016138574A3 (fr) | 2018-10-12 |
| RU2016138574A (ru) | 2018-04-06 |
| WO2015134585A1 (fr) | 2015-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290994A (en) | Methods of diagnosing and treating conduct disorder | |
| IL246678A0 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| EP3500289A4 (fr) | Procédés de traitement de la trachéobronchomalacie | |
| EP3463350A4 (fr) | Méthode de traitement de la fibrose hépatique | |
| EP3341080A4 (fr) | Méthode de traitement du cancer | |
| EP3288383A4 (fr) | Méthodes de traitement du cancer | |
| EP3380121A4 (fr) | Méthode de traitement de troubles oculaires | |
| IL249071B (en) | Bleaching and shive reduction process for non-wood fibers | |
| EP3423488A4 (fr) | Méthodes de traitement du cancer | |
| EP3391873A4 (fr) | Procédé et ensemble de traitement capillaire | |
| EP3375440A4 (fr) | Méthode de traitement de la mucosite | |
| EP3522934A4 (fr) | Compositions et méthode pour le traitement de la rénopathie | |
| EP3389634A4 (fr) | Méthodes de traitement du cancer | |
| EP3405203A4 (fr) | Méthodes de traitement du cancer | |
| EP3630732A4 (fr) | Méthode et molécules | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| EP3440112A4 (fr) | Méthodes de traitement du cancer | |
| DK3233071T3 (da) | Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme | |
| EP3313417A4 (fr) | Méthodes de traitement de troubles auto-immuns et allo-immuns | |
| EP3448365A4 (fr) | Méthode de traitement de la constipation | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3331499A4 (fr) | Composition et méthode de traitement de troubles métaboliques | |
| EP3389652A4 (fr) | Méthodes de traitement du cancer | |
| PL3520308T3 (pl) | Aparatura i sposób rozmieszczania podramek | |
| MA41462A (fr) | Méthode de traitement de maladies |